Drugs / Dextofisopam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00486876 | Jun 2007 → Sep 2009 | irritable bowel syndrome | Pharmos | Completed | Missed primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-10-21 | Pharmos | Pharmos Corporation Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam pharmoscorp.com ↗ |
| 2009-04-02 | Pharmos | Pharmos Issues Business Update on Dextofisopam Trial and Financing pharmoscorp.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dextofisopam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00486876 ↗ |
| Known as | R-TOFISOPAM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107331 ↗ |
| Modality | Small molecule | — CHEMBL2107331 ↗ |
| Route | Oral | “take 3 capsules of the blinded study drug twice a day by mouth” NCT00486876 ↗ |